Transdermal Drug Delivery: Is it feasible for your drug?
Sponsored by: LTS Lohmann Therapy Systems
Date: 25 November
Time: 3PM London/10AM New York
Transdermal Therapeutic Systems: characteristics, advantages and success stories
Alternative drug delivery methods form an important part of the current global pharma market and its differing patient profiles and needs. Increasingly, drug manufacturers and patients are looking at innovative and diverse drug delivery methods to reach the needs of a wider demographic.
TTS (Transdermal Therapeutic Systems) should be considered alongside more traditional methods of delivery such as oral and hypodermic injections. TTS provides a wide range of benefits which includes easy self administration; minimal pain levels; automatic time-lapsed delivery; low-risk of infection (in comparison to syringes) and direct contact with the treatable area, amongst others.
This webinar will show the components and science of a TTS (using case studies of current LTS clients), and how it can be used to provide a genuine alternative to current drug delivery methods – and be considered as a first choice dosage form.
Features and benefits of using a patch to address disease areas will be discussed, highlighting the market potential and increased market share associated with the development of the product.
Case Study 1: Novartis Exelon Patch – the only patch on the market which treats all stages of Alzheimer's: By 2014 has been approved in 90 countries and has achieved 92% of overall Exelon sales - which amounts to over USD 1 billion in revenue.
Case Study 2: UCB Neupro Patch – the only FDA approved patch which treats Parkinson's Disease: UCB reported in early 2014 that more than 229,000 patients were prescribed Neupro across 41 countries.
Case Study 3: MundiPharma Norspan Patch – which tackles pain. Became Mundipharma's number two international pharmaceutical product in 2012.
Please join this webinar for an analysis of the current trends and future developments of TTS, including some of the offerings from the LTS Lohmann team to aid you in the development of alternative drug delivery methods for your current and future product portfolios.
Dr. Peter Klaffenbach,
Head of Pharmaceutical Development
Dr. Peter Klaffenbach has been in transdermal drug delivery systems development for over 20 years and is now in charge of pharmaceutical development of LTS. Prior to joining LTS, Peter was managing director at the German drug delivery company Labtec (now tesa-Labtec) and head of pharmaceutical development at 3M drug delivery in Germany.
Dr. Iris Schnitzler,
Marketing and Sales Intelligence
Iris joined LTS about 15 years ago. She started as head of R & D at an LTS subsidiary focussing on patch technologies for the cosmetic industry. She held several positions in this organization including Head of Business Development and Head of Sales. In 2013, Iris moved on to the parent company LTS where she now is responsible for marketing and sales intelligence. Iris holds a Ph.D. in Chemistry.
Key Learning Objectives
- Understand the potential of transdermal therapeutic systems (TTS) in the pharmaceutical industry.
- Get to know different transdermal patch systems and how to overcome the skin barrier.
- Learn to understand the suitability of an API for a transdermal system.
- Learn in which cases a TTS could be the first choice or an alternative application form for your API and when a line extension with a TTS makes sense.
- Formulation Scientist
- Drug Delivery Scientists
- R&D Scientist
- Formulation Pharmacist
- Heads of Research and Development
- Head of Pharmaceutical Technology
- Director of Formulation
- Director Formulation Development
- Head of Product Development
- Business Development Managers
- Product Managers
- Innovation Managers
- Heads of Innovation Technology